Women with HIV who gained weight during pregnancy after starting dolutegravir-based treatment were less likely to experience birth outcomes such as premature birth, stillbirth or an infant that was small for gestational age, analysis of a large clinical trial has shown.
Weight gained during pregnancy was more likely to be maintained in the year after giving birth by women taking dolutegravir than those taking efavirenz, especially if dolutegravir was taken with tenofovir alafenamide.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.